Gilead Sciences (GB:0QYQ)
UK Market

Gilead Sciences Stock Analysis & Ratings

GB:0QYQ Stock Chart & Stats

Day’s Range$59.82 - $63.63
52-Week Range$53.95 - $90.85
Previous Close$62.87
Average Volume (3M)13.06K
Market Cap$79.04B
P/E Ratio17.5
Next EarningsJul 27, 2022
Dividend Yield2.88 (4.55%)
Smart Score9
EPS (TTM)3.58



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $53.95 and its highest was $90.85 in the past 12 months.
    What is Gilead Sciences’s market cap?
    Gilead Sciences’s market cap is $79.04B.
      What is Gilead Sciences’s price target?
      The average price target for Gilead Sciences is $68.57. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $84.00 ,the lowest forecast is $54.00. The average price target represents 8.82% Increase from the current price of $63.015.
        What do analysts say about Gilead Sciences?
        Gilead Sciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
          When is Gilead Sciences’s upcoming earnings report date?
          Gilead Sciences’s upcoming earnings report date is Jul 27, 2022 which is in 67 days.
            How were Gilead Sciences’s earnings last quarter?
            Gilead Sciences released its earnings results on Apr 28, 2022. The company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.804 by $0.316.
              Is Gilead Sciences overvalued?
              According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
                Does Gilead Sciences pay dividends?
                Gilead Sciences pays a Quarterly dividend of $0.73 which represents an annual dividend yield of 4.55%. Gilead Sciences’s last Quarterly dividend payment was on Jun 29, 2022. Gilead Sciences’s upcoming ex-dividend date is Jun 14, 2022
                  What is Gilead Sciences’s EPS estimate?
                  Gilead Sciences’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Gilead Sciences have?
                  Gilead Sciences has 1,250,000,000 shares outstanding.
                    What happened to Gilead Sciences’s price movement after its last earnings report?
                    Gilead Sciences reported an EPS of $2.12 in its last earnings report, beating expectations of $1.804. Following the earnings report the stock price went down -2.15%.
                      Which hedge fund is a major shareholder of Gilead Sciences?
                      Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 2B.


                        Gilead Sciences Stock Analysis

                        Smart Score
                        Price Target
                        ▲(8.82% Upside)
                        Moderate Buy
                        The Gilead Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Gilead Sciences

                        Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.

                        Similar Stocks
                        Price & Change
                        Roche Holding
                        Bristol Myers
                        Johnson & Johnson

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis